Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOBI Podhaler in Non-CF Bronchiectasis
NCT02102152Unknown
- Sponsor
- Rabin Medical Center
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tobramycin in Non-cystic fibrosis bronchiectasis (NCFB) (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Number of exacerbations at 52 weeks. Status: unknown.
02
Drugs
tobramycin
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT02102152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102152.